Smart drug ‘cuts risk of acute myeloid leukemia relapse and death’

13 November 2012

A smart drug could improve survival rates in older people with acute myeloid leukemia, new research has shown.

It was found that people who took the drug, called Gemtuzumab Ozogamicin (GO), were around 22 per cent less likely to relapse, and 13 per cent less likely to die from the disease.

Research from Cardiff University found that 68 per cent of participants on the new treatment relapsed within three years.

This was compared to 76 per cent of those who went for the standard treatment, according to the results, which were published in the Journal of Clinical Oncology.

Furthermore, 25 per cent of people on the smart drug were still alive after three years, compared to 20 per cent of people who received the standard treatment.

Chief investigator Professor Alan Burnett, School of Medicine, said: "These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects."

Posted by Jeanette Royston

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)